🎉 $25 OFF your evaluation — Use code 25OFF at checkout
CBDV
Cannabidivarin
Pronounced: see-bee-dee-VAR
CBDV (Cannabidivarin) is a non-psychoactive minor cannabinoid. Learn about CBDV, the CBD analog being studied for epilepsy and autism spectrum disorder. Discover the latest research and clinical trial results..
Boiling Point
356°F (180°C)
Formula
C₁₉H₂₆O₂
Legal Status
Legal federally when derived from hemp; not scheduled
What is CBDV?
CBDV (cannabidivarin) is a non-psychoactive propyl analog of CBD, isolated in 1969. While structurally similar to CBD, it has a shorter side chain which may affect its pharmacological properties. CBDV shows little activity at CB1 receptors but demonstrates affinity for CB2 receptors and modulates TRP channels. It's being actively studied for epilepsy and autism spectrum disorder (ASD), with several clinical trials underway.
How CBDV Works
CBDV demonstrates minimal binding to CB1 receptors but shows affinity for CB2 receptors. More notably, it modulates transient receptor potential (TRP) channels, particularly TRPV1, which are involved in pain perception and neural signaling. Research suggests CBDV may affect glutamate-GABA balance in the brain, which is relevant to both epilepsy and autism spectrum disorders.
Researched Effects
Anticonvulsant
Moderate EvidenceClinical trials are evaluating CBDV for various seizure disorders, including Dravet syndrome variants.
✓ Compliant Language
Being studied in clinical trials for seizure disorders
✗ Avoid Saying
Treats or cures epilepsy
Autism Spectrum Support
Emerging ResearchResearch shows CBDV may affect glutamate-GABA balance in the basal ganglia, relevant to ASD.
✓ Compliant Language
Early research exploring potential for autism spectrum support
✗ Avoid Saying
Treats autism
Anti-nausea
Emerging ResearchPreclinical studies suggest antiemetic properties similar to CBD.
✓ Compliant Language
Early research suggests anti-nausea potential
✗ Avoid Saying
Cures nausea
Sources
Medical Applications
Epilepsy (Rett Syndrome)
Moderate EvidencePhase 1 clinical trial evaluating safety and efficacy in girls with Rett syndrome.
Autism Spectrum Disorder
Emerging ResearchHuman neuroimaging and animal studies show effects on glutamate-GABA systems relevant to ASD.
Dosing Guidance
Limited human dosing data available. Clinical trials have used various doses. As research is ongoing, no standard dosing recommendations exist outside of clinical settings.
Safety Information
CBDV appears to be well-tolerated in early clinical studies. As a non-psychoactive cannabinoid similar to CBD, it does not produce intoxication. More research is needed on long-term safety.
Potential Side Effects
- Limited data available
- Generally well-tolerated in trials
- May cause fatigue
- Possible digestive effects
Drug Interactions
Not well-studied. May inhibit CYP450 enzymes similarly to CBD. Consult physician if taking other medications, especially anti-epileptic drugs.
Scientific References
Manna I, et al. • Pharmacological Research (2021)
PubMed ID: 33895189
Comprehensive overview of CBDV therapeutic potential for epilepsy and autism.
Pretzsch CM, et al. • Translational Psychiatry (2019)
PubMed ID: 31748505
CBDV affected glutamate-GABA balance in adults with and without ASD.
Zamberletti E, et al. • Neuropharmacology (2019)
PubMed ID: 31447649
CBDV restored hippocampal endocannabinoid signaling in autism model.
Hurley EN, et al. • Epilepsia (2022)
PubMed ID: 35364618
Safety and efficacy trial in girls with Rett syndrome.
Frequently Asked Questions
What is CBDV?
CBDV (cannabidivarin) is a non-psychoactive cannabinoid similar to CBD but with a shorter side chain. It's being actively studied for epilepsy and autism spectrum disorder.
How is CBDV different from CBD?
CBDV is a propyl analog of CBD with a shorter molecular side chain. While both are non-psychoactive, they may have different pharmacological effects. CBDV shows particular promise for neurological conditions.
Is CBDV being studied for autism?
Yes. Human neuroimaging studies show CBDV affects glutamate-GABA balance in brain regions relevant to autism. Clinical research is ongoing to evaluate its therapeutic potential.
Quick Facts
- Full Name
- Cannabidivarin
- Category
- minor Cannabinoid
- Psychoactive
- No
- Boiling Point
- 356°F (180°C)
- Formula
- C₁₉H₂₆O₂
Want to explore CBDV-rich products with a doctor?
Find a DoctorRelated Cannabinoids
Medical Disclaimer
This content is for educational purposes only and is not medical advice. Consult a healthcare provider before using cannabis products.
Individual Variation
Cannabis affects everyone differently based on genetics, tolerance, and other factors. What works for one person may not work for another.
Start Low, Go Slow
Always begin with the lowest effective dose and increase gradually to minimize risk of adverse effects.